I read with great interest the article by Chen et al. [1] evaluating the impact of proton pump inhibitors (PPIs) on antiplatelet effect of clopidogrel by conducting a meta-analysis of comparative concomitant use of clopidogrel with PPIs versus clopidogrel without PPIs, with the endpoint being cardiovascular events. The authors conducted a comprehensive search using multiple databases. Thirteen articles were included in their article and only seven were analyzed in the final module. Heterogeneity was found across the study and they concluded that there is an obvious discrepancy between the randomized control trials (RCTs) and the observational trials studied, and recommended large-scale RCTs to ascertain the true effects of PPIs on clopidogrel with respect to cardiovascular events.
展开▼
